A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children

YUAN Jin-Jing; WU De; WANG Wen-Wen; DUAN Jun; XU Xiao-Yan; TANG Jiu-Lai

doi:10.7499/j.issn.1008-8830.2106042

PDF(692 KB)

Chinese Journal of Contemporary Pediatrics ›› 2021, Vol. 23 ›› Issue (8) : 786-790. DOI: 10.7499/j.issn.1008-8830.2106042

CLINICAL RESEARCH

A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children

YUAN Jin-Jing, WU De, WANG Wen-Wen, DUAN Jun, XU Xiao-Yan, TANG Jiu-Lai

Author information +

History +

Abstract

Objective To study the clinical effect of mouse nerve growth factor (mNGF) in the treatment of children with global developmental delay (GDD). Methods A prospective clinical trial was conducted in 60 children with GDD who were treated in the First Affiliated Hospital of Anhui Medical University between July 2016 and July 2017. These children were randomly divided into two groups: conventional rehabilitation treatment and mNGF treatment group (n=30 each). The children in the conventional rehabilitation treatment group were given neurodevelopmental therapy, and those in the mNGF treatment group were given mNGF treatment in addition to the treatment in the control group. The evaluation results of the Gesell Developmental Scale were compared between the two groups before and after treatment. Results Before treatment and after 1.5 months of treatment, there was no significant difference in the developmental quotient (DQ) of each functional area of the Gesell Developmental Scale between the mNGF treatment and conventional rehabilitation treatment groups (P>0.05). After 3 months of treatment, the mNGF treatment group had significantly higher DQs of gross motor, fine motor, and personal-social interaction than the conventional rehabilitation treatment group (P?0.05). The incidence rate of transient injection site pain after injection of mNGF was 7% (2/30), and there was no epilepsy or other serious adverse reactions. Conclusions In children with GDD, routine rehabilitation training combined with mNGF therapy can significantly improve their cognitive, motor, and social abilities.

Key words

Global developmental delay / Mouse nerve growth factor / Clinical effect / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

YUAN Jin-Jing, WU De, WANG Wen-Wen, DUAN Jun, XU Xiao-Yan, TANG Jiu-Lai. A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children[J]. Chinese Journal of Contemporary Pediatrics. 2021, 23(8): 786-790 https://doi.org/10.7499/j.issn.1008-8830.2106042

References

1 李晓捷. 儿童常见疾病康复指南[M]. 北京: 人民卫生出版社, 2020: 34.
2 Mithyantha R, Kneen R, McCann E, et al. Current evidence-based recommendations on investigating children with global developmental delay[J]. Arch Dis Child, 2017, 102(11): 1071-1076. DOI: 10.1136/archdischild-2016-311271. PMID: 29054862. PMCID: PMC5738593.
3 Jeong JW, Sundaram S, Behen ME, et al. Differentiation of speech delay and global developmental delay in children using DTI tractography-based connectome[J]. AJNR Am J Neuroradiol, 2016, 37(6): 1170-1177. DOI: 10.3174/ajnr.A4662. PMID: 26797142. PMCID: PMC4907870.
4 Dornelas LF, Duarte NM, Morales NM, et al. Functional outcome of school children with history of global developmental delay[J]. J Child Neurol, 2016, 31(8): 1041-1051. DOI: 10.1177/0883073816636224. PMID: 26936059.
5 Bélanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability[J]. Paediatr Child Health, 2018, 23(6): 403-419. DOI: 10.1093/pch/pxy093. PMID: 30919832. PMCID: PMC6234423.
6 Choo YY, Agarwal P, How CH, et al. Developmental delay: identification and management at primary care level[J]. Singapore Med J, 2019, 60(3): 119-123. DOI: 10.11622/smedj.2019025. PMID: 30997518. PMCID: PMC6441684.
7 Sone Y, Takatori S, Ochi E, et al. Nerve growth factor facilitates the innervation of perivascular nerves in tumor-derived neovasculature in the mouse cornea[J]. Pharmacology, 2017, 99(1-2): 57-66. DOI: 10.1159/000450582. PMID: 27694752.
8 Zhao M, Li XY, Xu CY, et al. Efficacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients[J]. Neural Regen Res, 2015, 10(5): 819-828. DOI: 10.4103/1673-5374.156989. PMID: 26109961. PMCID: PMC4468778.
9 许凤丽, 纪红, 宫为大, 等. 鼠神经生长因子穴位注射联合Bobath法治疗运动发育迟缓患儿临床疗效[J]. 陕西中医, 2021, 42(5): 650-653. DOI: 10.3969/j.issn.1000-7369.2021.05.027.
10 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5)[M]. 5th ed. Arlington VA: American Psychiatric Association, 2013: 79.
11 孔娟, 梁少珍, 陈海凤, 等. 出生早期体重增长速率对早产儿矫正12月龄时神经发育的影响[J]. 中国当代儿科杂志, 2021, 23(3): 236-241. DOI:10.7499/j.issn.1008-8830.2010108. PMID: 33691915. PMCID: PMC7969198.
12 Yoshida T, Hiraiwa A, Ibuki K, et al. Neurodevelopmental outcomes at 3 years for infants with congenital heart disease and very-low birthweight[J]. Pediatr Int, 2020, 62(7): 797-803. DOI: 10.1111/ped.14160. PMID: 31957091.
13 Li YH, Anderson LA, Ginns EI, et al. Cost effectiveness of karyotyping, chromosomal microarray analysis, and targeted next-generation sequencing of patients with unexplained global developmental delay or intellectual disability[J]. Mol Diagn Ther, 2018, 22(1): 129-138. DOI: 10.1007/s40291-017-0309-5. PMID: 29209992.
14 徐艳红, 李静, 唐久来. 儿童全面性发育落后的高危因素、临床特征和预后[J]. 中华实用儿科临床杂志, 2016, 31(10): 783-786. DOI: 10.3760/cma.j.issn.2095-428X.2016.10.015.
15 Alamri A, Aljadhai YI, Alrashed A, et al. Identifying clinical clues in children with global developmental delay/intellectual disability with abnormal brain magnetic resonance imaging (MRI)[J]. J Child Neurol, 2021, 36(6): 432-439. DOI: 10.1177/0883073820977330. PMID: 33295251.
16 范晨雨, 谢鸿宇, 吴毅. 早期康复训练促进脑卒中神经重塑机制的研究进展[J]. 中国康复医学杂志, 2020, 35(11): 1377-1380. DOI: 10.3969/j.issn.1001-1242.2020.11.021.
17 Rocco ML, Soligo M, Manni L, et al. Nerve growth factor: early studies and recent clinical trials[J]. Curr Neuropharmacol, 2018, 16(10): 1455-1465. DOI: 10.2174/1570159X16666180412092859. PMID: 29651949. PMCID: PMC6295934.
18 Antonov SA, Manuilova ES, Dolotov OV, et al. Effect of nerve growth factor on neural differentiation of mouse embryonic stem cells[J]. Bull Exp Biol Med, 2017, 162(5): 679-683. DOI: 10.1007/s10517-017-3686-1. PMID: 28364186.
19 Paoletti F, Malerba F, Ercole BB, et al. A comparative analysis of the structural, functional and biological differences between mouse and human nerve growth factor[J]. Biochim Biophys Acta, 2015, 1854(3): 187-197. DOI: 10.1016/j.bbapap.2014.12.005. PMID: 25496838.
20 Wang QZ, Zhao HC, Zheng TH, et al. Otoprotective effects of mouse nerve growth factor in DBA/2J mice with early-onset progressive hearing loss[J]. J Neurosci Res, 2017, 95(10): 1937-1950. DOI: 10.1002/jnr.24056. PMID: 28345280. PMCID: PMC5561496.
21 Yin XJ, Dong L, Wei W, et al. Effect of mouse nerve growth factor on the expression of glial fibrillary acidic protein in hippocampus of neonatal rats with hypoxic-ischemic brain damage[J]. Exp Ther Med, 2013, 5(2): 419-422. DOI: 10.3892/etm.2012.827. PMID: 23408790. PMCID: PMC3570183.
22 Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease[J]. JAMA Neurol, 2015, 72(10): 1139-1147. DOI: 10.1001/jamaneurol.2015.1807. PMID: 26302439. PMCID: PMC4944824.
23 Rafii MS, Tuszynski MH, Thomas RG, et al. Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial[J]. JAMA Neurol, 2018, 75(7): 834-841. DOI: 10.1001/jamaneurol.2018.0233. PMID: 29582053. PMCID: PMC5885277.
24 Acosta CM, Cortes C, MacPhee H, et al. Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair[J]. CNS Neurol Disord Drug Targets, 2013, 12(8): 1242-1256. DOI: 10.2174/18715273113129990087. PMID: 23844684.
25 李晓捷. 儿童康复学[M]. 北京: 人民卫生出版社, 2018: 159.
26 中国医师协会神经修复学分会儿童神经修复学专业委员会. 婴幼儿脑损伤神经修复治疗专家共识[J]. 中华实用儿科临床杂志, 2019, 34(1): 2-8. DOI: 10.3760/cma.j.issn.2095-428X.2019.01.002.
27 赵会玲, 冯欢欢, 李晓捷, 等. 注射用鼠神经生长因子联合康复训练治疗脑性瘫痪患儿的临床疗效[J]. 中华实用儿科临床杂志, 2019, 34(16): 1237-1240. DOI: 10.3760/cma.j.issn.2095-428X.2019.16.011.
28 邹小兵, 李咏梅. 儿童发育迟缓及发育障碍的早期干预和管理[J]. 中国实用儿科杂志, 2016, 31(10): 756-760. DOI: 10.7504/ek2016100609.